Recursion Pharmaceuticals

RXRXPhase 3

Salt Lake City, United StatesFounded 2013recursion.com

Recursion Pharmaceuticals aims to decode biology and radically improve lives by applying artificial intelligence and automation to drug discovery. Its core asset is the Recursion OS, a comprehensive platform that generates and analyzes petabytes of proprietary biological data to fuel an internal pipeline of potential first-in-class and best-in-class therapies. The company has advanced several programs into clinical trials, secured strategic partnerships with industry leaders, and is building one of the most powerful supercomputers in biopharma to scale its operations.

Market Cap

$1.7B

Founded

2013

Focus

AI / Machine LearningSmall Molecules

RXRX · Stock Price

USD 3.253.51 (-51.92%)

Historical price data

AI Company Overview

Technology Platform

The Recursion Operating System (OS) is an integrated AI-powered drug discovery platform that combines massive proprietary biological datasets, automated high-throughput wet labs, and supercomputing to map disease biology and design novel therapeutics.

Pipeline Snapshot

8 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
REC-2282 + Placebo	Neurofibromatosis Type 2	Phase 2/3
REC-4881	AXIN1 Gene Mutation	Phase 2
REC-3964	Recurrent Clostridioides Difficile Infection	Phase 2
REC-994 + Placebo	Cerebral Cavernous Malformation	Phase 2
REC-4881 + Placebo	Familial Adenomatous Polyposis	Phase 1/2

Funding History

Total raised: $870M

IPO$436MUndisclosedApr 15, 2021

Series D$239MBaillie GiffordDec 15, 2020

Series C$121MLeaps by BayerSep 15, 2019

Series B$60MMubadala Investment CompanyNov 15, 2017

Opportunities

Validating its AI platform with successful clinical readouts could unlock immense value, positioning Recursion as a leader in industrialized drug discovery.

Expansion into new therapeutic areas beyond oncology and rare disease, and securing additional major pharmaceutical partnerships, represent significant growth avenues.

Risk Factors

The company faces high clinical development risk, as its AI-derived hypotheses must prove effective and safe in humans.

It also carries substantial platform validation risk and depends on significant capital to fund its expensive, integrated operations of wet labs, supercomputing, and clinical trials.

Competitive Landscape

Recursion competes with other AI-driven drug discovery firms like Exscientia, Insilico Medicine, and BenevolentAI. Its key differentiators are the immense scale of its proprietary biological data generation, its closed-loop Recursion OS platform, and its ownership of a dedicated supercomputer (BioHive-2), aiming to industrialize the entire discovery process.

Publications

Patents

Pipeline